KALUNDBORG, Denmark, Nov 14 (Reuters) – Steam rises from
pipes at a giant industrial complex on the edge of the Baltic
Sea whose success is a testament to the world’s diabetes and
Novo Nordisk’s Kalundborg factory, 100 km west of
Copenhagen, makes half the planet’s insulin for diabetics,
putting it on a list of global sites the United States sees as
vital to its interests, according to a WikiLeaks cable in 2010.
NEW YORK/LONDON (Reuters) – The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients.
Encouraging results in early-stage trials were announced for separate vaccines from Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.
LONDON (Reuters) – The world is losing the battle against diabetes as the number of people estimated to be living with the disease soars to a new record of 382 million this year, medical experts said on Thursday.
The vast majority have type 2 diabetes – the kind linked to obesity and lack of exercise – and the epidemic is spreading as more people in the developing world adopt Western, urban lifestyles.
LONDON, Nov 12 (Reuters) – An experimental GlaxoSmithKline
drug, designed to fight heart disease in a new way,
failed to meet its main goal in a major late-stage clinical
study, dealing a blow to one of the company’s biggest new
Darapladib’s inability to reduce the risk of heart attacks
and strokes in the first of two big Phase III clinical studies
is disappointing, but not a huge surprise. Many analysts already
had low expectations for the project.